In pharma, an integrated delivery network (IDN) is a health system that owns or jointly manages hospitals, physician groups, and often outpatient, post-acute, and sometimes insurance services under one organization, and makes many treatment and purchasing decisions centrally for all of them. For pharmaceutical, biotech, and medical device companies, that central decision-making is the point. A formulary decision, a treatment pathway, or a clinical protocol set at the IDN level can shape how thousands of patients across many sites are treated, so IDNs are planned and engaged as accounts rather than one physician at a time.
Quick answer: An IDN, also called a health system, combines hospitals and physician groups under common ownership or joint management. It usually has its own pharmacy and therapeutics committee, clinical pathways, and quality and population health leaders. Medical affairs engages those stakeholders with non-promotional scientific information and plans the work account by account, while commercial and market access teams keep their own, separate account plans.
There is no single official definition, and "IDN" and "health system" are used interchangeably in the industry. The Agency for Healthcare Research and Quality publishes several research definitions on its Defining Health Systems page. The one used for its Compendium of U.S. Health Systems describes an organization with at least one hospital and at least one group of physicians providing comprehensive care, connected to each other and to the hospital through common ownership or joint management.
In practice, the IDNs that matter most to a pharma account team are those large enough to standardize care across many sites. Many also run their own health plan, specialty pharmacy, or accountable care arrangements, which gives them a direct financial stake in the cost and outcomes of the treatments their clinicians choose. That puts them between a provider and a payer.
An IDN account is a group of people, not a single customer. The roles medical affairs teams usually map are:
The same physician may be both a treating clinician and a member of the P&T committee, and the information they can receive depends on which role they are acting in.
Medical affairs engages IDN stakeholders with balanced scientific information: clinical data, real-world evidence, and answers to the questions a committee raises while it reviews a product. That work is scientific exchange at account level, and it stays non-promotional. Some companies have field roles dedicated to this account-level work, alongside MSLs who cover individual experts.
Economic information has its own rules. FDA's guidance on manufacturer communications with payors, formulary committees, and similar entities, final in 2018 and reissued as a revised draft in June 2026, covers health care economic information shared with audiences that have expertise in health care economic analysis, such as a formulary committee. It does not apply to clinicians making individual prescribing decisions. For an IDN, that means a budget-impact model can go to the P&T committee under that guidance but not to a prescriber in the same system. HEOR teams usually build that evidence, and medical affairs often presents it.
The discipline behind this work is often described as value, evidence, and outcomes, which is covered in the glossary entry on VEO in pharma.
Because the decisions are spread across committees and people, IDN work needs a written account plan: the scientific goals for the system, the stakeholders and their roles, the evidence each one needs, what has been shared, and what changed as a result. Without that record, a team often cannot say whether a year of meetings moved a pathway or a formulary decision. Commercial and market access teams work the same IDNs with their own plans and goals, and the medical plan is kept separate so the scientific engagement stays non-promotional.
TikaValue and Outcomes is a scientific account planning workspace for medical affairs on IDNs and payers. The account, its linked hospitals and plans, the stakeholders, the plan, and what happened sit on one medical record, with formulary context beside the plan.
An IDN, or integrated delivery network, is a health system that owns or jointly manages hospitals and physician groups and makes formulary, pathway, and purchasing decisions centrally. Pharma companies plan and engage IDNs as accounts because those central decisions shape treatment across many sites.
In industry use, largely yes. AHRQ's research definition of a health system, an organization with at least one hospital and at least one physician group connected through common ownership or joint management, describes what most pharma teams mean by an IDN.
Usually the pharmacy and therapeutics committee, clinical pathway and service line leaders, quality and population health leaders, pharmacy and specialty pharmacy leaders, and the specialists who influence those decisions and treat patients.
With non-promotional scientific information for the system's committees and clinical leaders, planned in a written account plan that is kept separate from commercial plans. Health care economic information goes to formulary committees and similar audiences under FDA's payor communications guidance.
If your team plans health system accounts in decks and trackers, we can walk through one IDN account with your own stakeholders.
Book a 20-minute walkthrough →